No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity
-
- Hirosawa Takuya
- Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan
-
- Morimoto Naoki
- Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan
-
- Miura Kouichi
- Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan
-
- Tahara Toshiyuki
- Department of Gastroenterology, Saiseikai Utsunomiya Hospital, Japan
-
- Murohisa Toshimitsu
- Department of Gastroenterology, Dokkyo Medical University, Japan
-
- Okamura Yukishige
- Department of Gastroenterology, Sano Kousei General Hospital, Japan
-
- Sato Takashi
- Department of Gastroenterology, Nasu Red Cross Hospital, Japan
-
- Numao Norikatsu
- Department of Gastroenterology, Haga Red Cross Hospital, Japan
-
- Imai Masato
- Department of Gastroenterological Surgery, Utsunomiya Memorial Hospital, Japan
-
- Tano Shigeo
- Department of Gastroenterology, Shin-Oyama City Hospital, Japan
-
- Murayama Kozue
- Department of Gastroenterology, Koga Red Cross Hospital, Japan
-
- Kurata Hidekazu
- Department of Gastroenterology, Tochigi Medical Center Shimotsuga, Japan
-
- Ozawa Iwao
- Department of Hepatobiliary Surgery, Tochigi Cancer Center, Japan
-
- Fukaya Yukimura
- Department of Internal Medicine, Nasu Minami Hospital, Japan
-
- Yoshizumi Hiroaki
- Department of Internal Medicine, Kamitsuga General Hospital, Japan
-
- Watanabe Shunji
- Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan
-
- Tsukui Mamiko
- Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan
-
- Takaoka Yoshinari
- Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan
-
- Nomoto Hiroaki
- Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan
-
- Isoda Norio
- Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan
-
- Yamamoto Hironori
- Division of Gastroenterology, Department of Medicine, Jichi Medical University, Japan
Search this article
Abstract
<p>Objective Regional disparities were observed in the outcomes of interferon (IFN)-based therapy for chronic hepatitis C virus (HCV) infection in a Japanese nationwide study. However, whether or not these regional disparities are observed in the outcomes of direct-acting antiviral drugs, including sofosbuvir (SOF) plus ribavirin (RBV) therapy, remains unclear. </p><p>Methods We conducted a multicenter study to assess the efficacy of SOF plus RBV therapy for HCV genotype 2 infection in Tochigi Prefecture and its vicinity, in which IFN-based therapy yielded a low sustained virologic response (SVR) rate. In addition, we divided Tochigi Prefecture into six regions to examine regional disparities in the SVR. </p><p>Patients We enrolled patients with chronic HCV genotype 2 infection. </p><p>Results Of the 583 patients enrolled, 569 (97.6%) completed the treatment, and 566 (97.1%) also complied with post-treatment follow-up for 12 weeks. The overall SVR12 rate was 96.1% by per protocol and 93.7% by intention-to-treat analyses. No marked differences were observed in the SVR12 between subjects ≥65 and <65 years of age. Although large gaps were observed in the characteristics of patients and accessibility to medical resources, there was no significant difference in the SVR12 rate among the six regions in Tochigi Prefecture. </p><p>Conclusion SOF plus RBV therapy was effective for HCV genotype 2 infection in an area where IFN-based therapy had previously shown unsatisfactory results. In addition, no regional disparities in the SVR12 were observed in Tochigi Prefecture. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 58 (4), 477-485, 2019-02-15
The Japanese Society of Internal Medicine
